# OnCo record paper-actg-a5263-kaposi-sarcoma-resource-limited-krown-lancet-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-actg-a5263-kaposi-sarcoma-resource-limited-krown-lancet-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-actg-a5263-kaposi-sarcoma-resource-limited-krown-lancet-2020" ;
  schema:name "ACTG A5263/AMC 066: three chemotherapy regimens with antiretroviral therapy for advanced AIDS-associated Kaposi sarcoma in resource-limited settings"@en ;
  schema:description "For people with HIV and advanced Kaposi sarcoma in Africa and Brazil, paclitaxel with antiretroviral therapy kept far more patients free of progression at a year than either oral etoposide or bleomycin with vincristine, both of which were stopped early for being worse."@en ;
  schema:url <https://onco.cc/key-papers/paper-actg-a5263-kaposi-sarcoma-resource-limited-krown-lancet-2020/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(19)33222-2>, <https://pubmed.ncbi.nlm.nih.gov/32145827/> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(19)33222-2> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Krown SE, Moser CB, MacPhail P, et al." ;
  onco:cancers <https://onco.cc/cancers/kaposi-sarcoma/> ;
  onco:drugs <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/bleomycin/>, <https://onco.cc/drugs/vincristine/> ;
  onco:trials <https://onco.cc/trials/actg-a5263/> ;
  onco:journals <https://onco.cc/journals/lancet/> .